RAYMONDA RASTEGAR: Open Payments
NPI 1609888403 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$65,343 in 143 payments from 20 companies in 2025. Trend: 2023 $60,690 · 2024 $20,055 · 2025 $65,343
Speaker / faculty: $53,782Travel & lodging: $7,619Food & beverage: $3,941
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 33 | $62,647 |
| AstraZeneca Pharmaceuticals LP | 13 | $366 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 14 | $321 |
| Merck Sharp & Dohme LLC | 9 | $228 |
| Alnylam Pharmaceuticals Inc. | 9 | $226 |
| Esperion Therapeutics, Inc. | 10 | $206 |
| Lilly USA, LLC | 8 | $193 |
| BIOTRONIK INC. | 1 | $161 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $156 |
| BridgeBio Pharma, Inc. | 7 | $154 |
Products named: Ozempic, JARDIANCE, AMVUTTRA, VERQUVO, NEXLETOL, WAINUA, BIOMONITOR, LOKELMA.
Industry payments across NY — which companies pay providers there.
